Table 5.
The effect of Matrix Model treatment and MPH on METH Positive Urine test (MPUT) 1
| Variable | Group | Baseline | Week 3 | Week 6 | Week 9 | Week 12 | P-value* | OR (95% CI) |
|---|---|---|---|---|---|---|---|---|
| MPUT | Matrix (n = 20) | 20 (100) | 19 (95) | 18 (90) | 16 (80) | 16 (80)a | < 0.001 | 2.59 (0.87–7.75) |
| Methylphenidate (n = 22) | 22 (100) | 20 (90.9) | 18 (81.8) | 16 (72.7) | 13 (59.1) | 4.95 (1.79–13.68) | ||
| Matrix combination with methylphenidate (n = 21) | 21 (100) | 19 (90.5) | 17 (81) | 12 (57.1) | 8 (38.1) | 7.63 (2.82–20.67) | ||
| Control (n = 22) | 22 (100) | 21 (95.5) | 21 (95.5) | 20 (90.9) | 21 (95.5)b | Reference |
1 All variables are presented as number (%)
* GEE analysis (generalized estimating equations)
a: Significant difference between Matrix and Matrix combination with methylphenidate groups
b: Significant difference between Control with Methylphenidate and Matrix combination with methylphenidate groups